U.S. Packaging Stock News

Butterfly Network (BFLY) is back on investors’ radar after reporting record fourth quarter revenue, 41% year-over-year growth and its first quarter of positive operating cash flow, supported by its Butterfly Embedded platform and Midjourney partnership. See our latest analysis for Butterfly Network. The share price has been volatile around the recent earnings and guidance, with a 27.18% 7 day share price return reversing sharply into an 18.84% 1 day decline. At the same time, the 1 year total...

CNO Financial Group has released its 2025 Form 10-K, outlining past-year operational performance, a planned exit from the Worksite Division’s fee services business by the first half of 2026, and a three-year TechMod program to upgrade its technology infrastructure. An interesting angle for investors is how concentrating on core insurance operations while overhauling technology may reshape CNO’s efficiency profile and operating return on equity over time. Now we’ll explore how CNO’s TechMod...

In recent weeks, nVent Electric reported record Q4 2025 revenue with quarterly sales surpassing US$1.00 billion and full-year sales reaching US$3.90 billion, while also affirming a regular quarterly dividend of US$0.21 per share payable on May 8, 2026. The company’s expanding product set in liquid cooling and infrastructure solutions, together with a tripled order backlog of US$2.30 billion, underlines how exposed it is to long-term demand trends in data centers and renewable energy-related...

V2X (VVX) is back in focus after reporting record quarterly revenue and earnings, locking in a US$4.3b T-6 Aircraft award and other billion-dollar contracts, and issuing upbeat 2026 revenue guidance. See our latest analysis for V2X. Those contract wins and upbeat 2026 outlook sit alongside a 27.16% 90 day share price return and a 48.66% 1 year total shareholder return, which suggests momentum has been building as earnings and backlog news has come through. If V2X’s run has you thinking about...

Alnylam Pharmaceuticals (NasdaqGS:ALNY) reported a new update on its Phase 1 clinical study of ALN-4285. The RNA based drug targets a novel disease related protein and the company released preliminary safety and pharmacokinetic data. The announcement marks an early step in assessing ALN-4285 in human subjects in a clinical setting. Alnylam, a company focused on RNA based medicines, has been building a pipeline of investigational therapies that aim to modulate disease related proteins at the...

In recent months, Ross Stores reported solid third-quarter 2025 results with 10% total sales growth, 7% comparable store gains, an 11.6% operating margin despite tariff pressures, and the completion of its 90-store 2025 expansion program. At the same time, Ross’s off-price model is benefiting from increased access to discounted inventory amid retail bankruptcies, supporting the company’s margin structure and reinforcing positive sentiment among research analysts and independent...

If you are wondering whether Occidental Petroleum's current share price really reflects what you are getting for your money, this article walks through the numbers so you can judge the value for yourself. The stock last closed at US$53.08, with returns of 2.4% over 7 days, 18.4% over 30 days, 25.2% year to date, 11.1% over 1 year, negative 8.9% over 3 years and 80.4% over 5 years. This gives you a mixed picture to keep in mind as you weigh the valuation. Recent coverage of Occidental has...

Otis Worldwide (OTIS) has introduced its Arise MOD Prime and Arise MOD Plus elevator modernization packages in North America, giving building owners more choice over how they update low to mid rise residential and commercial elevators. See our latest analysis for Otis Worldwide. At a share price of US$92.56, Otis has a 30 day share price return of 4.47%. Its 1 year total shareholder return shows a 5.52% decline, which contrasts with a 54.07% total shareholder return over five years and...

American Bitcoin (ABTC) has closed out FY 2025 with Q4 revenue of US$78.3 million and a basic EPS loss of US$0.06, alongside trailing twelve month revenue of US$185.2 million and EPS of US$0.17. Over the past few quarters the company has seen revenue move from US$11.6 million in Q3 2024 to US$12.3 million in Q1 2025, US$30.3 million in Q2 2025, US$64.2 million in Q3 2025 and US$78.3 million in Q4 2025, while quarterly EPS has ranged from a loss of US$1.99 in Q1 2025 to a profit of US$0.06 in...

Apple Hospitality REIT (APLE) is back in focus after reporting fourth quarter and full year 2025 results that came in ahead of earnings and revenue expectations, despite softer midweek and government travel demand. See our latest analysis for Apple Hospitality REIT. The latest earnings beat has come against a backdrop of mixed returns, with a 6.8% 1 month share price return and a 3.1% 3 month share price return. The 1 year total shareholder return is a 10.4% loss despite regular monthly...

Churchill Downs Incorporated recently reported fourth-quarter and full-year 2025 results, with revenue rising to US$665.9 million in the quarter and US$2.93 billion for the year, while net income and earnings per share eased compared with 2024. Alongside earnings, the company continued to build out its historical horse racing footprint, including the February 2026 opening of the Marshall Yards Racing & Gaming venue in Kentucky, underlining management’s focus on expanding higher-margin racing...

Monster Beverage (MNST) closed out FY 2025 with fourth quarter revenue of US$2.1 billion and basic EPS of US$0.46, alongside trailing twelve month revenue of US$8.3 billion and EPS of US$1.95 that followed earnings growth of 26.3% over the last year. Over recent periods, the company has seen quarterly revenue move from US$1.9 billion in Q3 2024 to US$2.0 billion in Q4 2024, then to US$1.9 billion in Q1 2025 and US$2.1 billion in both Q2 and Q4 2025, while basic EPS shifted from US$0.38 in Q3...

Ionis Pharmaceuticals (NasdaqGS:IONS) received FDA Priority Review for olezarsen in severe hypertriglyceridemia, indicating an expedited regulatory timeline. New Phase 3 analyses for DAWNZERA, an RNA targeted therapy for hereditary angioedema, are scheduled for presentation at a major scientific forum. These developments focus on two rare disease programs that are central to Ionis’s drug development efforts. Ionis Pharmaceuticals focuses on RNA targeted medicines, with a portfolio that...

NIO (NYSE:NIO) has received its first major external funding for its intelligent driving chip unit GeniTech (Shenji) from Chinese investors. The company has created a new subsidiary focused on battery technology. NIO has also entered into a new cooperation with Bosch around smart electric vehicle technologies. NIO, listed on the NYSE under the ticker NIO, is known for its premium smart electric vehicles and in-house technology efforts. The fresh capital for GeniTech, together with the new...

Brightstar Lottery (NYSE:BRSL) has appointed Mariangela Zappia, an international diplomat, as an independent director to its board. The company has announced that CFO Max Chiara will not stand for board re election, with his departure expected after the upcoming shareholder meeting. Brightstar recently secured a nine year renewal of the Italy Lotto licence, supporting a multiyear capital allocation plan and expansion initiatives. Brightstar Lottery, listed on the NYSE under ticker BRSL,...

Why the activist letter matters for First Industrial Realty Trust (FR) On February 26, Land & Buildings Investment Management publicly challenged First Industrial Realty Trust (FR), criticizing its boardroom culture and urging changes it says are needed to address the REIT’s trading discount and unlock more value. See our latest analysis for First Industrial Realty Trust. At a share price of US$63.14, First Industrial Realty Trust has logged an 11.03% 1 month share price return and a 14.42% 1...

Olema Pharmaceuticals (OLMA) has been drawing attention after recent share price swings, with the stock at US$24.20 and mixed returns over the past month, past 3 months, and year to date, prompting fresh investor scrutiny. See our latest analysis for Olema Pharmaceuticals. While the recent 1 day and 30 day share price returns show modest declines from US$24.20, the very large 1 year and 3 year total shareholder returns suggest earlier optimism around Olema Pharmaceuticals is now being...

In February 2026, Everus Construction Group, Inc. reported fourth-quarter 2025 sales of US$1,011.47 million and net income of US$55.28 million, alongside full-year 2025 sales of US$3.75 billion and net income of US$201.77 million, and issued 2026 revenue guidance of US$4.1 billion to US$4.2 billion. Management also underscored that Everus is actively pursuing accretive acquisitions, backed by a strong balance sheet, expanded corporate development capabilities and a broader M&A pipeline...

Dole plc has reported fourth-quarter 2025 sales of US$2,366.16 million with a net loss of US$2.66 million, alongside full-year 2025 sales of US$9,172.91 million and net income of US$51.32 million, while affirming a US$0.085 per-share quarterly dividend and completing a 300,000-share buyback. Beyond the headline figures, Dole exited its Fresh Vegetables division, authorized up to US$100 million of share repurchases, and is targeting at least US$400 million of adjusted EBITDA for 2026,...

Analyst reaction to Duke Energy’s nuclear reliability milestone Duke Energy (DUK) has drawn fresh attention after reporting record 2025 nuclear fleet reliability of 96.9%, tied to roughly US$600 million in federal nuclear production tax credits passed through to customers. Recent analyst commentary has linked this operational update to a stronger earnings outlook and increased confidence in the company’s long term execution. This has prompted many investors to take a closer look at the...

Q3 2026 results set up a cleaner earnings story for Elastic (ESTC) Elastic (ESTC) has just posted Q3 2026 revenue of US$449.9 million with basic EPS of US$0.07, alongside trailing twelve month revenue of about US$1.7 billion and a basic EPS loss of US$0.80, giving investors a clearer read on both recent momentum and the still negative full year earnings base. The company has seen quarterly revenue move from US$365.4 million in Q2 2025 to US$449.9 million in Q3 2026, while basic EPS has...

Atlanta Braves Holdings (BATR.K) is back in focus after its latest quarterly earnings and the announcement of BravesVision, a new in-house local broadcast platform that is set to reshape how the team monetizes its media rights. See our latest analysis for Atlanta Braves Holdings. The latest earnings beat and BravesVision announcement come after a 10.79% 1 month share price return and a 9.73% year to date share price return, while the 5 year total shareholder return of 46.93% points to...

In February 2026, Lennar disclosed that the Illinois State Treasurer submitted a shareholder proposal seeking vote-by-share-class reporting, while another proposal urged the company to move toward a one-share, one-vote structure, ahead of its April 8, 2026 annual meeting. These governance-focused proposals highlight growing investor pressure for greater transparency and voting equality at Lennar, even as the company continues expanding communities like Cedar Springs in Alabama. We’ll now...

Vericel (VCEL) just paired record fourth quarter results with fresh 2026 guidance. This puts its MACI franchise, expanding sales force, and new manufacturing plans in the spotlight for investors watching the stock. See our latest analysis for Vericel. The earnings and 2026 guidance arrived alongside some pressure on the share price, with a 1-day share price return of a 5.31% decline and a 7-day share price return of a 6.33% decline. The 1-year total shareholder return of a 30.43% decline...